Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
NGM Biopharmaceuticals, Inc
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04913337CT.gov Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endocervical Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ngm707 (this asset) | NGM Biopharmaceuticals, Inc | P1/2 | CCC · 48 |
| Pembrolizumab | NGM Biopharmaceuticals, Inc | P1/2 | CCC |
| ngm831 | NGM Biopharmaceuticals, Inc | P1 | CC |
| ngm438 | NGM Biopharmaceuticals, Inc | P1 | CC |
Other indications for ngm707
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | B · 58 |
| Head And Neck Squamous Cell Carcinoma | — | P1/2 | CC · 45 |
| Mesothelioma | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ngm707 in Endocervical Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ngm707-endocervical-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →